期刊文献+

抗生素治疗厌氧菌性心包炎的研究进展 被引量:3

Progress in the Treatment of Pericarditis Caused by Anaerobic Bacteria
下载PDF
导出
摘要 自厌氧菌性心包炎患者中分离出的主要致病厌氧菌包括革兰阴性杆菌(大多为脆弱拟杆菌属)、消化链球菌属、梭杆菌、梭形杆菌属、双岐杆菌属及放线菌属等。引起厌氧菌性心包炎的途径主要是:(1)邻近感染灶的播散;(2)心脏内感染灶的播散;(3)血行播散;(4)胸部贯通伤或心胸外科手术时的直接种植。由于近年来厌氧革兰阴性杆菌对青霉素及其他抗生素的耐药增加,因此厌氧菌的鉴定与药物敏感试验对厌氧菌性心包炎的治疗至关重要。厌氧菌性心包炎内科治疗主要是应用对致病厌氧菌有效的抗生素。 This review describes progress in the management of pericarditis associated with anaerobic bacterial infection. The predominant anaerobes isolated from patients with pericarditis are Gram-negative bacilli (mostly Bacteroides fragilis), Peptostreptococcus, Clostridium, Fusobacterium, Bifidobacterium and Actinomyces spp. The primary factors that may be responsible for the development of anaerobic pericarditis include: (I) pathogens spread from a contiguous focus of infection, (2) pathogens spread from a focus of infection within the heart, (3) haematogenous infection, and (4) direct inoculation as a result of a thoracic penetrating injury or cardiothoracic surgery. In recent years, penicillin- and other antimicrobial-resistance of anaerobic Gram-negative bacilli have significantly increased, identification and antimicrobial susceptibility testing, therefore, become essential for the management of infections caused by anaerobic bacteria. The mainstay of medical treatment for pericarditis associated with anaerobes is the antibiotic therapy effective against abovespecified organisms.
作者 邓万俊
出处 《国外医药(抗生素分册)》 CAS 2010年第2期58-62,共5页 World Notes on Antibiotics
关键词 心包炎 厌氧菌 抗生素 pericarditis anaerobic bacteria antimicrobial agents
  • 相关文献

参考文献22

  • 1Lee DG.Clinical significance of anaerobic infection [J]. Korean J Intern Med, 2009, 24:11.
  • 2Brook I. Pericarditis caused by anaerobic bacteria[J]. Int J Antimicrob Agents, 2009, 33(4):297.
  • 3Saito T, Senda K, Takakura S, et al. Anaerobic bacterenia: the yield of positive anerobic blood cultures:patients characteristics and potential risk factors [J]. Clin Chem Lab Med, 2003, 4:293.
  • 4Brook I. Clinical review. Bacteremia caused by anaerobic bacteria in children [J]. Critical Care, 2002, 6(3):205.
  • 5Brook I. Pericarditis due to anaerobic bacteria [J]. Cardiol, 2002, 97(2):55.
  • 6Aikat S, Ghaffari S. A review of pericardial diseases: clinical ECG and hemodynamic features and management [J]. Clev Clin J Med, 2000, 67:903.
  • 7Koehler R, Mone M, Kimball E, et al. Clostridium difficile pericarditis complicating pseudomembranous colitis in a trauma patient [J]. J Trauma, 2003, 55:771.
  • 8Shinagawa N, Yamaguchi E, Takahashi T, et al. Pulmonary actinomycosis followed by pericarditis and intractable pleuritis [J]. Intern Med, 2002, 41:319.
  • 9Makaryus AN, Latzman J, Yang R, et al. A rare case of Actinomyces israelii presenting as pericarditis in a 75-year-old man [J]. Cardiol Rev, 2005, 13:125.
  • 10Chairperson BM, Seferovic PM, Ristic AD, et al.Guidelines on the diagnosis and management of pericardial diseases: executive summary [J]. Eur Heart J, 2004, 25:587.

同被引文献32

  • 1李从荣,金正江,詹,丁俊清,李艳,彭少华.奥硝唑治疗口腔厌氧菌感染的临床与实验研究[J].中华医院感染学杂志,2004,14(3):325-327. 被引量:40
  • 2马政辉,黄秀娜,刘海英.厌氧菌鉴定方法[J].检验医学,2007,22(1):99-101. 被引量:5
  • 3Bartlett JG. How important are anaerobic bacteria in aspi- ration pneumonia: when should they be treated and what is optimal therapy[J]. Infect Dis Clin NortAmer, 2013, 27 (1): 149-155.
  • 4Hecht DW. Anaerobes: antibiotic resistance, clinical sig- nificance, and the role of susceptibility testing [EB/OL]. http://link.springer.com/article/10.1007% 2Fs15010- 012- 0389-4, 2013-02-01.
  • 5Hostler C J, Chen LF. Fidaxomicin for treatment of clostrid- ium difficile-associated diarrhea and its potential role for prophylaxis[J]. Exp Opin Pharmacoth, 2013, 14(11): 1529-1536.
  • 6Brook I. Antimicrobial treatment of anaerobic infections[J]. Exp Opin Pharmacoth, 2011, 12(11 ): 1691 - 1707.
  • 7Dubreuil LJ, Mahieux S, Neut C, et al. Anti-anaerobic ac- tivity of a new [3-1actamase inhibitor NXL104 in combina- tion with 13-lactams and metronidazole[J], lnt J Antimicr Ag, 2012, 39(6): 500-504.
  • 8Davies TA, Flamm RK, Lynch AS. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone[J]. Int J Antimierob Agents, 2012, 39(6):534-538.
  • 9Betriu C, Culebras E, G6mez M, et al.Comparative in vi- tro activity of ceftobiprole against Gram-positive cocci [J]. lnt JAntimicrob Agents, 2010, 36(2): 111-113.
  • 10Kreskena M, K6ber-Irrganga B, L~ifferb J, et al. In vitro activities of ceftobiprole combined with amikacin or levo- floxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology[J], lnt J An- timicrob Agents, 2011, 38(1):70-75.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部